Skip to main content

BRIGHT MINDS BIOSCIENCES INC.

For the period ended Mar 31, 2026. Filed Jun 3, 2026.

View on SEC.gov

About this filing

What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.

Mar 31, 2026 · Filed Jun 3, 2026

Use the contents to explore the available documents and sections.

DRUG$23.00+11.1%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

EX-99.3 · Performance Graph

Performance Graph* *

The following graph compares the cumulative shareholder return on an investment of $100 in the Common Shares of the Company from September 30, 2020 to September 30, 2025, with a cumulative total shareholder return to the S&P 500 Index Fund over the same period.

Over the five-year period ended September 30, 2025, the Company's share price performance was volatile, reflecting its development-stage operations. During the same period, executive compensation remained relatively stable and was primarily comprised of base salary and long-term equity awards. As a result, while annual compensation did not fluctuate directly with year-to-year market movements, the equity-based component aligns management's interests with long-term shareholder value.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.